IL2RG Recombinant Monoclonal Antibody

IL2RG, also known as the common gamma chain (γc) or CD132, serves as an essential shared subunit for multiple cytokine receptors including those for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. This critical role in cytokine signaling makes IL2RG indispensable for lymphocyte development and immune function, with mutations in this gene causing X-linked severe combined immunodeficiency (SCID). Understanding IL2RG biology has significant implications for immunology research and cancer studies, particularly in contexts involving immune cell proliferation and therapeutic targeting.

This recombinant monoclonal antibody (clone 6F3) offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures lot-to-lot reproducibility, giving you confidence that your experimental results will remain comparable across studies and over time. The antibody is produced as a human IgG4 isotype and purified by affinity chromatography, delivering a high-purity reagent suitable for demanding applications.

Validation through functional ELISA demonstrates robust binding activity, with EC50 values of 33.73–41.04 ng/mL against immobilized Rhesus macaque IL2RG protein. This cross-species reactivity extends the antibody's utility for translational research, with confirmed reactivity against both human and cynomolgus samples. For ELISA applications, dilutions ranging from 1:5000 to 1:50000 are recommended, providing flexibility to optimize signal-to-background ratios for your specific experimental conditions.

Supplied in a glycerol-based PBS buffer for stability, this antibody supports researchers investigating immune signaling pathways, lymphocyte biology, and related oncology applications where IL2RG function intersects with disease mechanisms.